Recently, the China International Economic and Trade Arbitration Commission (“CIETAC”) issued a decision in a private equity investment dispute between an investor represented by JT&N and a private fund manager. The CIETAC accepted the advice of JT&N’s legal team, upheld all of our client’s arbitration claims, and ordered the private fund manager to return all of the investment funds and compensate for the loss of interest. More
On June 13, 2023, the IPO application and listing project of Zhejiang KAYO Motor Co., Ltd. (浙江华洋赛车股份有限公司) (hereinafter referred to as “KAYO Motor”) was reviewed and approved by the 29th meeting of the Listing Committee of the Beijing Stock Exchange (北交所) in 2023 without any comments. More
Recently, Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. (君合盟生物制药（杭州）有限公司) (hereinafter referred to as “Junhemeng”) has successively completed Series A and Series A+ financing of hundreds of millions of yuan. Series A financing was led by Tonghua County State-Owned Assets Investment Holding Group Co., Ltd. (通化国投) and followed by many institutions such as Guangdian Capital (光点资本); Series A+ financing was jointly invested by the original shareholders, Guangdian Capital and 3E Bioventures Capital (本草资本). More
On June 2, 2023, Chijet Motor Company, Inc. (“Chijet Motor”) successfully merged with Jupiter Wellness Acquisition Corp., a special purpose acquisition company (SPAC), and was officially listed on the NASDAQ Main Board with the stock code of CJET. More
Recently, the Beijing Municipal Higher People’s Court issued a second instance judgment on the eight trademarks including “中联大药房” (“China Associate Pharmacy”) (“the contested trademark”) appealed by China Associate (Group) Co., Ltd. (“China Associate”), which reversed the first instance judgment and upheld the registration of China Associate’s core brand “China Associate Pharmacy”. More